IGBA informs that Jonathan Kimball is no longer part of the staff of the Association for Accessible Medicines (AAM), our U.S. IGBA Member, and hence, is no longer in the position as IGBA Chair. Subsequently, David Gaugh, AAM's Interim CEO, has taken up the Director role for AAM on the IGBA Management Committee. To ensure continuity, IGBA is very pleased to announce that the IGBA Management Committee has unanimously nominated David Gaugh as the new IGBA Chair for the rest of 2023. David has been involved within IGBA since 2012, and was previously the IGBA Chair in 2014, where he lead the then Alliance to be legalized under Swiss law to become the Association. David again chaired the IGBA in 2018.
IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that experts and leaders from the local and global generic and biosimilar medicines industries, Government and regulatory agencies, academia and other stakeholders are meeting from 15 to 16 February in Orlando, Florida to discuss key topics affecting worldwide patient access to affordable quality-assured medicines, such as...
The International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Jonathan Kimball, Vice President of Trade and International Affairs of the Association for Accessible Medicines (AAM), Vice-Chair IGBA and Vice Chair of the IGBA International Trade and Intellectual Property Committee in 2022, is taking over the position of IGBA Chair for 2023 from Vivian Frittelli, Chief Executive of Generic and Biosimilar Medicines of Southern Africa (GBM). Adrian van den Hoven, Director General of Medicines for Europe, steps in as IGBA Vice-Chair.
- IGBA taking action to tackle shortages of antibiotic medicines (December 2022)
- IGBA Releases Report on Factors Affecting the Supply of Generic Medicines (December 2022)
- IGBA introductory statement at the Geneva Trilateral Symposium on The Covid 19 Pandemic: Response, Preparedness, Resilience, convened by WHO, WIPO and WTO (December 2022)
- IGBA joins the Fight the Fakes Alliance (December 2022)